comparemela.com

Latest Breaking News On - Sumitomo pharma america inc - Page 1 : comparemela.com

Lynch Carpenter Investigates Claims in Cencora, Inc Data

PITTSBURGH, May 29, 2024 (GLOBE NEWSWIRE) Cencora, Inc. recently announced that it suffered from a cybersecurity attack that occurred in February of.

United statesPatrick donathenCencora incLynch carpenterEndo pharmaceuticals incSumitomo pharma america incAbbvie incAcadia pharmaceuticals incGlaxosmithkline groupBayer corporationNovartis pharmaceuticals corporationRegeneron pharmaceuticals incGenetech inc incyte corporationDendreon pharmaceuticalsGenetech incIncyte corporation

Major Pharma Companies Affected by Cencora Data Breach

More than a dozen pharmaceutical companies have been affected by the Cencora cyberattack and data breach that occurred in February.

United statesRegeneron pharmaceuticals incAcadia pharmaceuticals incGenentech incMarathon pharmaceuticalsDendreon pharmaceuticalsBayer corporationEndo pharmaceuticals incExchange commissionPharming healthcare incBristol myers squibb companySunovion pharmaceuticals incGlaxosmithkline group of companiesNovartis pharmaceuticals corporationAbbvie incBristol myers squibb patient assistance foundation

Sumitomo Pharma America Announces Data Breach, Possibility Related to Incident at Cencora | Console and Associates, P C

On May 24, 2024, Sumitomo Pharma America, Inc. filed a notice of data breach with the Attorney General of Texas after discovering that confidential information that had been provided to.

United statesSumitomo pharma americaMore information about sumitomo pharma america incSumitomo pharma america incSumitomo pharma co ltdAttorney generalSumitomo pharma america dataInformation about sumitomo pharma americaPharma america

Vibegron Under Review for Men With OAB Symptoms Receiving BPH Treatment

The FDA has accepted the sNDA for vibegron for the treatment of men with overactive bladder symptoms receiving drug therapy for BPH.

Tsutomu nakagawaSumitomo pharma america incInternational prostate symptoms storageDrug administrationNew drug applicationSumitomo pharma america

Sumitomo Pharma : Posted Conference on FY2023 Financial Results

May 14, 2024 Sumitomo Pharma Co., Ltd. Sumitomo Pharma Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including.

Toru kimuraTsutomu nakagawaHisayoshi kashimaMotoyuki sakaibirthdateHiroshi niinumaTakashi kutsunaiMinoru usuiMotoyuki sakaiYoshio iteyaSaeko araiNobuhiro endoMayumi mochizukiKoji fujimotoDaishiro michimoriHiroshi nomuraSchool of science

vimarsana © 2020. All Rights Reserved.